“…Revascularization at 3 d, 5 d,7 d. Inhibited by infection At 1 d, 3 d, 4 d and 7 d ↑ CD11b + , CD206 + myeloid cells [ 321 ] 2021 | CCI (3 mm, 3 m/s, dwell time 85 ms) | Male C57Bl/6J mice (9–10 wks) | 1 d, 7 d, 1 year | Meninges, Meningeal ILCs (Innate lymphoid cells) | At 1,7d ↑ILC1-3. At 1y ↑ILC2/3 Metabolic dysregulation with ↓AMPKα1 at 1d *CCI + IL-33 (1μg) ↑pAMPKα | [ 298 ] 2021 |
CHIMERA (single × 1 & repeat × 4) | Male, Female C57Bl/6 mice (6–7 wks) | 1 d, 7 d | Whole brain MRI | At 1d & 7d ↑ meningeal enhancement in both single and repeat impacts | [ 305 ] 2022 |
CCI (0.5 mm or 1 mm, 5 m/s, d well undisclosed) | Male C57Bl/6J mice (9–10 wks) | 3 dpi, 6 wks | Dura mater–RNAseq, Whole mount meninges | 3dpi - ↑CD45+ myeloid (B cell) & CD11b+ cells 6 wks - ↑Ccl8, Il1β, Ccl2 Ccl7 ↑immune pathways, including interferon gamma response | [ 316 ] 2022 |
CCI (2 mm, velocity undisclosed) | Male C57Bl/6 mice (10 wks) | 3 d | Meningeal lymphatic endothelial cells (LECs) | Flow cytometry ↓ Lyve1 LECs Microarray ↑ DEGs involved in FCERI signaling, antibody-mediated complement, Inflammatory response | [ 307 ] 2022 |
Adapted CCI hit and run (closed head, 2 mm, 5.2 m/s, dwell time 100 ms) | Male C57Bl/6J mice (8–12 wks & 20 months) | 7 d, 1.5 m | Whole mount meninges Meninges for bulk & scRNA-seq | At 7d, ↑DEG s related to macrophages, fibroblasts, and adaptive immune cells. ↑IFNβ, IRF5, IFNAR1 At 1.5m ↑ collagen, fibroblasts ↑T/B cell DEG. |
…”